- Topic
21k Popularity
21k Popularity
141k Popularity
3k Popularity
18k Popularity
- Pin
- 🎉 Hey Gate Square friends! Non-stop perks and endless excitement—our hottest posting reward events are ongoing now! The more you post, the more you win. Don’t miss your exclusive goodies! 🚀
🆘 #Gate 2025 Semi-Year Community Gala# | Square Content Creator TOP 10
Only 1 day left! Your favorite creator is one vote away from TOP 10. Interact on Square to earn Votes—boost them and enter the prize draw. Prizes: iPhone 16 Pro Max, Golden Bull sculpture, Futures Vouchers!
Details 👉 https://www.gate.com/activities/community-vote
1️⃣ #Show My Alpha Points# | Share your Alpha points & gains
Post your - 🚀 ETH jumped to $4,600 this morning, up 8.69% in 24h!
Just shy of the $4,891 ATH—think it breaks through?
📍 Follow Gate_Square, vote and drop your reason.
🎁 4 winners split $100 Futures Voucher! - 💙 Gate Square #Gate Blue Challenge# 💙
Show your limitless creativity with Gate Blue!
📅 Event Period
August 11 – 20, 2025
🎯 How to Participate
1. Post your original creation (image / video / hand-drawn art / digital work, etc.) on Gate Square, incorporating Gate’s brand blue or the Gate logo.
2. Include the hashtag #Gate Blue Challenge# in your post title or content.
3. Add a short blessing or message for Gate in your content (e.g., “Wishing Gate Exchange continued success — may the blue shine forever!”).
4. Submissions must be original and comply with community guidelines. Plagiarism or re
Lyon: Remains optimistic about the development of Stone Pharmaceutical Group, maintaining a "highly confident outperform the market" rating.
Jin10 data reported on May 30 that Lyon published a research report indicating that although the sales of Enbipusi from Shanghai Pharmaceuticals (01093.HK) faced challenges, the first quarter performance still met expectations, with a year-on-year net profit fall of 8.4%. It is believed that Shanghai Pharmaceuticals' profits have bottomed out in the first quarter. In addition to the market's focus on SYS6010, the management also revealed that there are two other products that will achieve potential licensing cooperation, each exceeding $5 billion in scale. Lyon expressed continued optimism about Shanghai Pharmaceuticals' development, believing that its early R&D pipeline is competitive globally and has a differentiated innovative drug platform, maintaining a "highly confident outperform the market" rating for Shanghai Pharmaceuticals, with a target price of HKD 13.8.